BCA
CSTL icon

Berman Capital Advisors’s Castle Biosciences CSTL Stock Holding History

Berman Capital Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$2K Hold
43
– – ﹤0.01% 1673
2021
Q2 		$3K Buy
+43
New +$2.84K ﹤0.01% 1474

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
ZCI
Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

Berman Capital Advisors's CSTL Position: Q3 2021 in Review

Berman Capital Advisors held its Castle Biosciences (CSTL) position steady in Q3 2021 at 43 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1673.

Berman Capital Advisors first reported a position in CSTL in Q2 2021 and has held it in 2 quarters since. The position peaked at $3K in Q2 2021. 188 funds tracked by Wall St. Rank hold CSTL as of Q3 2021.

  • Berman Capital Advisors held 43 shares of Castle Biosciences worth $2K as of Q3 2021.
  • Berman Capital Advisors left its Castle Biosciences share count unchanged in Q3 2021.
  • Castle Biosciences made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1673 holding.
  • Berman Capital Advisors first reported a position in Castle Biosciences in Q2 2021 and has held it in 2 quarters since.
  • Berman Capital Advisors's Castle Biosciences position peaked at $3K in Q2 2021.
  • 188 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.